Cannabis-Based Drug Offers Hope for Weight Loss in Cancer Patients

A new medication developed by the UK biotech firm Artelo Biosciences is showing promise in helping cancer patients combat cachexia, a debilitating condition characterized by severe weight loss and muscle wasting. Approximately 80% of advanced cancer patients experience this condition, which can significantly impact their quality of life. Researchers believe this cannabis-based drug could stimulate appetite—leveraging the well-documented “munchies” effect often associated with marijuana use.

The experimental drug works by targeting cannabinoid receptors without entering the brain, which reduces the likelihood of producing a high. Formulated as a tablet, it was tested in clinical trials where participants gained an average of 6.4% of their body weight over a 12-week period. In contrast, those on a placebo experienced an average weight loss of 5.4%, according to reports from the Express.

Clinical Trial Insights

The study involved 25 participants suffering from various advanced cancers. Researchers utilized wearable monitoring devices to track changes in physical activity. Those taking the medication displayed increased movement, while placebo recipients tended to become less active. Despite the increased appetite stimulation, test subjects reported no noticeable increase in hunger levels.

Lead researcher Professor Barry Laird, a palliative care specialist at the University of Oslo, highlighted the profound impact of the drug. He noted that one patient could return to playing golf, while another enjoyed a weekend getaway. Laird addressed the emotional toll of cancer-related weight loss, stating, “There’s a huge degree of stress associated with cancer weight loss because eating is a core part of human existence.”

He emphasized that the ability to share meals with loved ones significantly enhances life quality for patients and their families. “Being able to return to the dinner table and enjoy a meal with their loved ones is extremely impactful,” Laird added during a presentation at a cachexia conference in Turin last month.

Future Prospects

Following the promising results of the initial trials, Artelo Biosciences plans to advance the medication into larger phase three studies. If these studies prove successful, the drug could potentially be available by 2028. Andy Yates, Artelo’s chief scientific officer, expressed confidence in the drug’s potential to not only improve patient quality of life but also save treatment costs.

Yates remarked, “We are confident we will be able to show that this drug can save treatment costs as well as helping improve the quality of life of patients, their families, and their carers.” As the medical community continues to explore innovative solutions for cancer-related challenges, this cannabis-based treatment may represent a significant step forward in addressing the complex needs of patients facing advanced illness.